跳至主要内容

Enzyme Catalysis

 As a CRO that advocates green drug research and development, Medicilon has always been committed to promoting the green upgrading of pharmaceutical processes through technological innovation. Medicilon has already used enzymes in process research and development, and relying on its strong chemical and biological background, Medicilon has established a the Enzyme Catalysis Technology Platform to screen catalytic enzymes for specific reaction types and establish corresponding enzyme libraries to assist process development and production.

Medicilon Enzyme Catalysis Service Platform

  • 01 Chemical Technology Platform

    Development of Pharmaceutical Intermediates and APls

    Functional Chemical Development

    02 Biotechnology Platform

    Enzyme Development and Applications

    Enzyme Production

    03 Quality Technology Platform

    Quality and Control Research

    Inspection and Testing Services

    Medicilon Enzyme Catalysis Service Platform.jpg
    Medicilon's Enzyme Catalysis Technology Platform includes chemical technology platform, biotechnology platform, and quality technology platform.  The platform focuses on the combination of chemical synthesis and biological enzyme catalytic synthesis, the development and application research of biological enzymes, and the R&D and production of pharmaceutical intermediates and APIs using green biotechnology.  At the same time, it provides high-end CRO, CDMO services, testing and quality research services to pharmaceutical companies.

Medicilon Enzyme Library

/d/image/20230920/650a7f843c54d.webp

KetoreductaseD-amino acid dehydrogenaseTransaminaseNitrile HydratasePhenylalanine LyaseHydroaminase
Cytochrome MonooxygenaseThreonine DehydrogenasePhosphokinaseEpoxide HydrolaseNitrilase
Alcohol OxidaseFormate DehydrogenaseNucleoside Phosphorylation (synthesis)AmidohydrolaseAldol Condensase
Monoamine OxidaseGlucose DehydrogenaseNitrilaseOther Specialized Enzymes
NitrileLactateLactate
ReductaseDehydrogenaseDehydrogenase
NitroreductasePhenylalanine Dehydrogenase
Imine ReductaseAmmonia Dehydrogenase
  • At present, Medicilon has successfully established dozens of major biological enzyme libraries, such as ketoreductase, ester hydrolase, imine reductase, nitroreductase, cyclooxygenase, amide hydrolase, for providing suitable biocatalytic solutions for various chemical transformations.  These integrated enzymatic services reduce costs, shorten time, and improve quality.  With the implementation of a large amount of projects, Medicilon enzyme library is also continuing to be optimized and expanded.  Medicilon will also carry out research on immobilized enzymes and coenzymes.

Medicilon’s R&D capabilities in the field of synthetic biology

  • With the continuous advancement of synthetic biology technology, more and more enzymes with specific catalytic functions are used as biocatalysts to achieve reactions that are difficult to achieve with chemical catalysts, and can be used as catalytic components to build functional modules of synthetic biology.  Medicilon has already established a presence in the field of synthetic biology. Through the assembly of different enzyme components, Medicilon has made breakthroughs in the design of synthetic routes for many target molecules and can provide a variety of services:
    Molecule and Strain ConstructionStrain Delection and DomesticationEnzyme Co-ExpressionMulti-Enzyme CatalysisBiocatalysisProtein ModificationFermentation MetabolismProtein PurificationFermentation OptimizationEnzyme Immobilization
    In the future, Medicilon, as a one-stop biopharmaceutical preclinical R&D service platform, will continue to explore and apply more innovative green chemical technologies to achieve more environmentally friendly, safe, efficient and economical process development and production, and create more innovative products for global clients.

评论

此博客中的热门博文

The Launch Meeting was Held by Medicilon and DAC Biotech of the Contract Research on ADC Preclinical Study

  Chuansha, Shanghai, Nov. 8th, 2019 — Medicilon held the launch meeting with Hangzhou DAC Biotech Co., Ltd to initiate the   preclinical study   of the antibody-drug-conjugate (ADC)  DXC005, including the   pharmacology study ,   DMPK study   and the   safety evaluation . Medicilon has previously completed integrated  preclinical research  on ADC drugs cooperating with DAC Biotech and other companies. Two of them has been approved by NMPA and entered Phase I clinical trials. About Hangzhou DAC Biotech Co., Ltd Hangzhou DAC Biotech, Co., Ltd was officially registered in HEDA Area, Hangzhou City, Zhejiang Province, China around the end of Year 2012, and is located nearby the bank of beautiful Qiantang River. The company focuses on developing conjugate of monoclonal antibody and small molecular cytotoxic drug, both of which are banded together with smart linkers. About Antibody-Drug-Conjugate (ADC) ADCs ...

Medicilon assisted Hangzhou DAC Biotech in approval of clinical study of ADC drug DAC-002

  On July 20, 2020, DAC Biotech’s new   ADC drug development , TROP2-ADC—DAC-002 was approved of clinical study by NMPA. for the indication of solid malignant tumor. Medicilon completed   preclinical pharmacokinetic  and toxicological studies in this project, accelerating the development process. DAC-002 is an ADC anti-Trop2 monoclonal antibody conjugated by an intelligent ligand against Tubulysin B analogue. It is used to treat Trop2 triple negative breast cancer, small cell lung cancer, non-small cell lung cancer and pancreatic cancer.Trop2 can promote the proliferation, invasion, metastasis and diffusion of tumor cells, and its high expression is closely related to the shortening of survival time and poor prognosis of tumor patients. Therefore, it is of great significance to study anti-tumor drugs targeted by Trop2. Reference: Medicilon Assists - The first China-made targeting folic acid receptor FRα ADC injection BAT8006 was approved for clinical use Medicilon As...

Medicilon and Binhui Biopharmaceutical Have Reached a Strategic Collaboration to Jointly Draw a New Blueprint for the Development of New Biological Drugs

  On March 18, Medicilon and Binhui Biopharmaceutical (Binui Bio) announced a strategic collaboration.  The two parties will work together to jointly explore the possibilities in cutting-edge fields such as oncolytic viruses, nucleic acid drugs and protein drugs. Gather and Work Together to Create Advantages      Facilitate the Research and Development of Oncolytic Viruses, Nucleic Acids, Proteins and Other Drugs As a one-stop biopharmaceutical comprehensive preclinical R&D service CRO, Medicilon has been developing and accumulating for 20 years, always adhering to the spirit of innovation, and has successfully constructed bi/multi-specific antibodies,  ADCs ,  mRNA vaccines ,  small nucleic acid drugs ,  PROTAC , and  CGT technical service platform  that have helped 421 INDs obtain clinical approval.  It is this outstanding achievement that has earned Medicilon wide recognition in the industry and laid a solid foundation f...